1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
AcouSort AB

AcouSort AB

ACOU.ST
AcouSort ABSE flagStockholm Stock Exchange
3.88
SEK
+0.03
- -
82.12MMarket Cap
AcouSort AB
ACOU.ST
(Stockholm Stock Exchange)

Recent

price

3.88

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.07
0.24
0.2
0.34
0.32
0.1
0.18
0.43
0.23
0.38
0.42
0.32
0.36
0.35
Revenue per Share
-0.01
0.01
-0.03
-0.1
-0.78
-0.87
-0.93
-0.7
-0.93
-1.04
-1.29
-1.01
-0.64
-0.49
Basic EPS, GAAP
- -
- -
-0.09
-0.03
-1.1
-0.71
-0.95
-0.62
-0.83
0.3
-2.37
-1.26
-0.89
-0.36
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.02
0.04
0.01
-0.03
-0.83
-1.48
-2.46
-2.97
-3.51
-4.42
-5.67
-6.07
-5.37
-4.85
Book Value per Share
0.02
0.04
0.01
1.24
0.45
1.46
0.48
0.72
2.33
1.23
1.55
0.27
0.61
0.41
Tangible Book Value per Share
11
8
8
8
8
10
10
11
13
13
13
15
19
21
Basic Weighted Avg Shares
1
2
2
3
2
1
2
5
3
5
6
5
7
7
Sales/Revenue/Turnover
-22.32
6.98
-18.73
-23.62
-244.64
-835.29
-519.72
-158.56
-406.65
-289.12
-315.97
-340.41
-159.39
-143.65
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
Depreciation Expense
- -
- -
- -
-1
-6
-9
-10
-8
-12
-14
-17
-15
-12
-11
Net Income, GAAP
- -
9.28
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-7.53
5.55
-17.71
-30.49
-244.64
-834.26
-520.31
-161.89
-408.18
-277.65
-308.8
-318.3
-177.34
-141.81
Profit Margin (%)
- -
- -
- -
-1
3
15
5
7
30
16
20
4
11
9
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
10
4
16
6
10
33
19
24
8
16
14
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
8.05
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
35.59
-127.84
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
57
56
61

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
17
13
22
Cash, Cash Equivalents & STI
12
6
15
Accounts Receivable, Net
- -
- -
- -
Inventories
3
3
3
Total Current Liabilities
3
2
13
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,299.82%
51.34%
92.61%
Free Cash Flow
277.63%
-205.39%
-10.78%
Net Income, GAAP
92.6%
11.79%
-19.4%
Sales/Revenue/Turnover
31.35%
13.57%
44.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
1
5
2025
2
2
1
2
7
2026
2
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.25
-0.32
-0.25
-0.19
-1.01
2025
-0.27
-0.14
-0.12
-0.12
-0.64
2026
-0.11
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Health House International Limited (HHI.AX)
Achyut Healthcare Ltd. (ACHYUT.BO)
Suzuken Co., Ltd. (9987.T)
Exlites Holdings International, Inc. (EXHI)
Ridgetech, Inc. (RDGT)
Healthlead Public Company Limited (HL.BK)
Business
AcouSort AB (publ) (ACOU.ST) develops acoustofluidic components and instruments for automated sample preparation in diagnostics, analytics, cell therapy processing, flow cytometry, and quality control applications; core products include separation modules for continuous cell washing, up-concentration, and isolation; trapping modules for capturing particles and cells in microfluidic systems; AQC modules for in-line optical analysis of suspensions; AcouPlasma modules enabling blood plasma separation from whole blood without centrifugation; benchtop research instruments such as AcouTrap for handling cells, extracellular vesicles, bacteria, and viruses in 96-well format, and AcouWash for label-free target cell separation from diverse samples; as well as evaluation kits for technology integration testing. Founded in 2010 and headquartered in Medicon Village, Lund, Sweden, the company targets life science instrument manufacturers, researchers, and clinicians primarily in Europe, North America, and Asia. Recent developments include Werfen's 2024 launch of the GEM Premier 7000 point-of-care blood gas analyzer incorporating AcouSort's hemolysis detection technology, generating minimum royalty income of SEK 5.25 million in 2025; a May 2025 rights issue raising SEK 24.9 million to fund OEM partnerships through 2027; extensions and new orders in 2025 from Central European diagnostic firms, a leading pharma for AcouWash quality control (EUR 11,300 extension in April), a US cell therapy partner, and UK sepsis management collaborator; March 2025 letter of intent with Bio-ReCell for stem and immune cell isolation from adipose tissue; November 2025 technology evaluation agreement with SeeQ Diagnostics for blood sample preparation; and ongoing collaborations with flow cytometer makers, GenSensor for bioreactor monitoring, and academic institutions like University of Ottawa.